Literature DB >> 25742236

Optimized protocol for (18)F-choline PET/CT in patients with biochemically relapsed prostate cancer: experiences on 250 consecutive cases.

Sotirios Chondrogiannis1, Maria Cristina Marzola, Gaia Grassetto, Lucia Rampin, Arianna Massaro, Patrick M Colletti, Domenico Rubello.   

Abstract

PURPOSE: We review acquisition F-choline PET/CT methodology, evaluate a new F-choline acquisition protocol for prostate cancer (PC), and propose a standardized acquisition protocol on F-choline in PC patients. MATERIALS: Two hundred fifty consecutive PC patients (mean age 72 years, mean PSA 7.9 ng/mL) were prospectively evaluated with F-choline PET/CT. An early scan of the pelvis (1 bed position of 4 minutes) was followed by a whole-body scan at 1 hour. Early and 1 delayed hour images of the pelvis were compared.
RESULTS: Twenty-one percent of patients (n = 57) with positive F-choline demonstrated abnormal local uptake; 18% of patients (n = 45) showed distant localization only; 23% of patients (n = 53) had both local and distant localization; 38% of patients (n = 38) did not show any pathological uptake. All early images showed absence of radioactive urine in ureters, bladder, or urethra with satisfactory visualization of the prostatic region. Considering the group of patients with local uptake only, the prostatic region uptake, confirmed by late images, was better visualized in the early phase in 32/57 cases (SUVmax 12.4 ± 3.2 vs. 7.3 ± 5.2, P <0.01). Instead distant lesions were visualized on both early and late images with similar uptakes values (SUVmax 9.8 ± 4.1 vs. 10.3 ± 4.5, P = N.S.).
CONCLUSION: Early F-choline images improve pelvic prostate cancer lesion clarity. All pathologic pelvic deposits (prostate, lymph nodes, bone) were visualized both in the early and late images.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25742236     DOI: 10.1097/RLU.0000000000000757

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

Review 1.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

2.  A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer.

Authors:  Spencer C Behr; Rahul Aggarwal; Youngho Seo; Carina M Aparici; Emily Chang; Kenneth T Gao; Dora H Tao; Eric J Small; Michael J Evans
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

3.  Optimization of temporal sampling for 18F-choline uptake quantification in prostate cancer assessment.

Authors:  Xavier Palard-Novello; Anne-Lise Blin; Florence Le Jeune; Etienne Garin; Pierre-Yves Salaün; Anne Devillers; Giulio Gambarota; Solène Querellou; Patrick Bourguet; Hervé Saint-Jalmes
Journal:  EJNMMI Res       Date:  2018-06-15       Impact factor: 3.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.